FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas

Oncology / Hematology News Burst

Source: FDA Center for Drug Evaluation and Research - What's New - April 13, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news